MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia
NCT ID: NCT00911066
Last Updated: 2013-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
72 participants
INTERVENTIONAL
2009-06-30
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MLN4924
MLN4924
MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:
* Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)
* Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)
* Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)
* Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)
* Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)
Azacitidine
Azacitidine
Azacitidine will be administered (IV or subcutaneous (SC)) on Days 8 to 12 and Days 15 and 16 in Cycle 1, and on Days 1 to 5 and Days 8 to 9 (Schedule D)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MLN4924
MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:
* Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)
* Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)
* Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)
* Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)
* Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)
Azacitidine
Azacitidine will be administered (IV or subcutaneous (SC)) on Days 8 to 12 and Days 15 and 16 in Cycle 1, and on Days 1 to 5 and Days 8 to 9 (Schedule D)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have the following diagnosis:
* AML or ALL (for the dose escalation phase only)including leukemia secondary to prior chemotherapy or resulting from an antecedent hematologic disorder, who have failed to achieve complete response (CR) or who have relapsed after prior therapy and are not candidates for potentially curative treatment.
* Acute Promyelocytic Leukemia (APL) patients are not eligible
* AML or ALL patients who are over age 60 and have not received prior therapy are also eligible if they are not candidates for standard induction chemotherapy
* High-grade MDS, defined as \> 10% blasts on bone marrow examination
* Low-grade MDS, defined as \< 10% blasts on bone marrow examination (Schedule B expansion cohort only)
* Patients who are willing to refrain from donating blood for at least 90 days after their final dose of MLN4924 and (for male patients) willing to refrain from donating semen for at least 4 months after their final dose of MLN4924
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
* Female patients who are postmenopausal, surgically sterile, or agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse
* Male patients who agree to practice 2 effective methods of contraception or abstain from heterosexual intercourse
* Voluntary written consent
* Suitable venous access
* Adequate clinical laboratory values during the screening period as specified in the protocol
* Patients who are on hydroxyurea may be included in the study and may continue on hydroxyurea while participating in this study.
Exclusion Criteria
* Any serious medical or psychiatric illness
* Treatment with any investigational products
* Systemic antineoplastic therapy or radiotherapy within 14 days before the first dose of study drug, except for hydroxyurea
* Major surgery within 14 days before the first dose of study drug
* Life-threatening illness unrelated to cancer
* Clinically uncontrolled central nervous system (CNS) involvement
* Known human immunodeficiency virus (HIV) positive
* Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
* Evidence of uncontrolled cardiovascular conditions as specified in the protocol
* Diarrhea \> Grade 1, based on the NCI CTCAE categorization
* Systemic treatment with prohibited medications
* Ongoing anticoagulant therapy (eg, aspirin, Coumadin, heparin) that cannot be held to permit bone marrow sampling
* Use of acetaminophen, acetaminophen-containing products, and statins are not permitted on the day before dosing, day of dosing, and day after dosing with MLN4924
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Millennium Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Millennium Pharmaceuticals, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University Medical Center
Stanford, California, United States
Robert H. Lurie Comprehensive Cancer Center Northwestern University
Chicago, Illinois, United States
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Institute for Drug Development
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Faessel HM, Mould DR, Zhou X, Faller DV, Sedarati F, Venkatakrishnan K. Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies. Br J Clin Pharmacol. 2019 Nov;85(11):2568-2579. doi: 10.1111/bcp.14078. Epub 2019 Sep 4.
Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M, Hua Z, Blakemore SJ, Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol. 2015 May;169(4):534-43. doi: 10.1111/bjh.13323. Epub 2015 Mar 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C15003
Identifier Type: -
Identifier Source: org_study_id